Renal insufficiency is a common complication early after hematopoietic stem cell transplantation (HSCT). Renal function as measured by creatinine clearance (CrCl) was prospectively evaluated in 47 patients undergoing allogeneic (n ¼ 22) or autologous (n ¼ 25) HSCT during the first 100 days. Renal dysfunction was classified as follows: Grade 0 (o25% decline in CrCl), Grade 1 (X25% decline in CrCl but o2 Â increase in serum creatinine), Grade 2 (X2 Â rise in serum creatinine but no need for dialysis) and Grade 3 (X2 Â rise in serum creatinine and need for dialysis). Thirty-three patients (70%) had Grade 1-3 renal dysfunction. Renal dysfunction was more common after myeloablative allogeneic HSCT (91%) than autologous HSCT (52%) (P ¼ 0.004), and was associated with a high risk of mortality (P ¼ 0.039). Sepsis in autologous HSCT patients and cyclosporine toxicity in allogeneic HSCT patients were associated with renal dysfunction. We conclude that autologous and allogeneic HSCT differ in the likelihood and causes of renal dysfunction.
Introduction
Hematopoietic stem cell transplantation (HSCT) is considered the best treatment option for many hematological malignancies, and transplant numbers have increased fivefold during the last decade. 1 Survival after HSCT depends on recovery from the effects of cytoreductive therapy, successful engraftment, prevention of infections and graft-versus-host disease (GVHD) and eradication of the underlying disease. 2 Renal insufficiency is a common organ dysfunction after HSCT. 3 Acute renal failure (ARF), defined as a doubling of the pretransplantation serum creatinine in the first 4 weeks after transplantation, occurs in 5-54% of HSCT recipients. [3] [4] [5] [6] Many factors including tumor lysis syndrome (TLS), marrow infusion toxicity, infections and nephrotoxicity of drugs contribute to ARF after HSCT. 4, 7 Several HSCT-specific syndromes of organ dysfunction such as hemolytic uremic syndrome (HUS) and sinusoidal obstruction syndrome (SOS) affect the kidney. 4, [8] [9] [10] [11] [12] Materials and methods
Patient selection
Forty-seven consecutive patients with hematological malignancies receiving myeloablative allogeneic or autologous HSCT at the Bone Marrow Transplantation Unit of Istanbul School of Medicine between May 2001 and July 2003 were prospectively studied for the development of renal dysfunction and organ failure during the first 100 days after HSCT. A review of medical records before transplantation including information on age, sex, baseline weight, stage and duration of the disease, renal, liver and pulmonary functions was undertaken. A detailed medical history with treatment types whether in standard doses or intensified and treatment lines were also recorded before HSCT. As renal insufficiency after HSCT is affected by renal injury from chemotherapy received before HSCT, even months or years before HSCT, patients in this study were required to have acceptable renal (creatinine clearance 460 ml/min), hepatic (aspartate aminotransferase, alanine aminotransferase, bilirubin and alkaline phosphatase o1.5 times normal), pulmonary (diffusing capacity of the lung for carbon monoxide 460% predicted) and cardiac functions (echocardiography showing a left ventricular ejection at rest 450%) before treatment with high-dose chemotherapy and HSCT. Our examinations of the patients conformed to good medical and laboratory practices and the recommendations of the Declaration of Helsinki on Biomedical Research involving Human Subjects. This study was approved by the Istanbul School of Medicine Clinical Studies Board.
Hematopoietic cell support and conditioning regimens
In autologous study group, all of the patients received peripheral blood progenitor cells and in allogeneic study group marrow or peripheral blood progenitor cells were administered to patients according to their disease status including risk of GVHD and time of cytopenia. The patients received conditioning regimens according to their underlying hematological malignancies and disease status. All allogeneic HSCT patients received myeloablativeconditioning regimen. The conditioning regimen consisted of busulfan and cyclophosphamide, except two, which included total body irradiation (TBI). All of the donors were HLA full-matched sibling but two unrelated. Cyclosporine A (CsA) (initiated intravenously as 3 mg/kg, daily switch to peroral as 5 mg/kg/day) and short-term methotrexate (15 mg/m 2 /day on day þ 1 and 10 mg/m 2 /day on days þ 3, þ 6 and þ 11) were used as acute GVHD prophylaxis. Blood CsA level was monitored as determining of trough level using enzyme-linked multiple immunoassay technique assay which was based on parent compound measurement. CsA whole blood trough levels were 200-400 ng/ml. Blood CsA level 4400 ng/ml was defined as the toxic level.
Patient monitoring
Blood studies and urine analyses were performed systematically at admission for a baseline evaluation. Patients were monitored during their entire hospital course for complications including sepsis (documented by positive blood cultures), hypotension (defined as systolic blood pressure (BP) o90 mm Hg) and organ toxicities. Renal function was assessed by serum creatinine concentration and a creatinine clearance calculated by the Cockcroft and Gault formula. 13 At least two measurements of BP were made each day during their entire hospital course. Laboratory parameters were measured on days À7, À1, 1, 3, 5, 7, 10, 12, 14, 16, 19, 21, 23, 26, 28, 33, 36, 40, 43, 46 , 50, 54, 57, 61, 64, 67, 71, 77, 85 and 92. Renal dysfunction was classified according to the serum creatinine concentration and creatinine clearance. Grade 0, or normal renal function, corresponded to a decrement in creatinine clearance of less than 25% from the baseline values. Grade 1 renal dysfunction corresponded to a less than twofold increase in serum creatinine with a decrease in creatinine clearance greater than 25% of baseline value. Grade 2 renal dysfunction corresponded to greater than or equal to twofold rise in serum creatinine concentration of the baseline value but no need for dialysis. Grade 3 renal dysfunction corresponded to patients with twofold rise in serum creatinine and need for dialysis. Grade 2 and 3 renal dysfunction was considered as severe renal dysfunction or ARF. A diagnosis of SOS of the liver was made according to the occurrence of two of the following events within 20 days of transplantation: hyperbilirubinemia (total serum bilirubin concentration 42 mg/dl), hepatomegaly or right upper quadrant pain of liver origin, and sudden weight gain (42% of baseline body weight) because of fluid accumulation. 9 
Statistical methods

Results
Patient baseline characteristics
The baseline characteristics of the 47 patients (22 patients in allogeneic HSCT group and 25 patients in autologous HSCT group) are shown in Table 1 . There were no differences in age, body surface area, baseline serum creatinine, creatinine clearance, serum albumin and BP levels between allogeneic and autologous HSCT groups. The diagnosis and conditioning regimens for each patient are shown in Table 1 . Different treatment protocols were used according to the diagnosis and the stage of the underlying diseases. Forty-two of the 47 patients received peripheral blood stem cells as stem cell source and five patients received bone marrow stem cells. In the autologous HSCT group, all the patients received peripheral blood stem cells.
Changes in BP levels after HSCT Although there was no statistically significant difference between the baseline mean BP levels of allogeneic and autologous HSCT groups (P ¼ 0.39), systolic BP levels were different according to time after HSCT between the groups. During the course of autologous HSCT, systolic and diastolic BP levels were lower than allogeneic HSCT within the first month (P ¼ 0.001 and Po0.001, respectively).
Changes in renal function after HSCT An analysis of the entire group revealed a rise in serum creatinine (0.7570.15 to 2.3471.89 mg/dl, Po0.001) and a decrease in calculated creatinine clearance (130.59731.18-71.47735.27 ml/min, Po0.001) from day À7 to mean day 43.85725.73. The changes in renal function were then analyzed based on the severity of renal dysfunction (Grades 0-3). Thirty-three out of 47 patients (70%) had Grade 1-3 renal dysfunctions within the 100 days of the allogeneic and autologous HSCT ( Table 1 ). The mean baseline (day À7) serum creatinine concentration and creatinine clearance of patients with renal dysfunction did not differ from patients with normal renal function (P ¼ 0.91 and P ¼ 0.53, respectively) ( Table 2 ). The mean baseline (day À7) serum creatinine concentration and creatinine clearance did not differ also among the four groups of renal dysfunction (P ¼ 0.81 and P ¼ 0.90, respectively). Patients with renal dysfunction had a mean maximum serum creatinine concentration of 2.3972.23 mg/dl on day 43724 after HSCT (Table 2) .
There was no difference between the ages of four groups at the time of HSCT (P ¼ 0.61). There were no differences in age, gender and hematological malignancies between patients with and without renal dysfunction (P ¼ 0.39, P ¼ 0.52 and P ¼ 0.48, respectively). Both groups did not differ with regard to baseline laboratory tests and conditioning regimens. However, baseline serum albumin levels o3.5 g/dl were correlated with the development of renal dysfunction (P ¼ 0.035). There was no difference between patients with and without renal dysfunction according to the source of stem cells (P ¼ 0.61).
Of all patients, 23 patients had severe renal dysfunction (Grade 2-3 renal dysfunction). The mean baseline (day À7) serum creatinine concentration and creatinine clearance of patients with severe renal dysfunction did not differ from patients with normal renal function or Grade 1 renal dysfunction (0.7770.38 mg/dl, 137.55752.4 ml/min versus 0.7470.15 mg/dl, 126.47728.95 ml/min (P ¼ 0.70 and P ¼ 0.38, respectively)). There were no differences in age, Table 2 Characteristics of patients with normal renal function or renal dysfunction Changes in renal function according to type of HSCT The differences in the rates of renal dysfunction were also examined in allogeneic versus autologous HSCT patients. Twenty patients (91%) with allogeneic HSCT and 13 patients (52%) with autologous HSCT developed various grades of renal dysfunction. Renal dysfunction and severe (Grades 2-3) renal dysfunction were found more common after myeloablative allogeneic HSCT than autologous HSCT during the first 100-day period (P ¼ 0.004) ( Table 1) . In allogeneic HSCT group, patients with renal dysfunction had a mean maximum serum creatinine concentration of 2.4971.91 mg/dl on day 51722, and in autologous HSCT group they had a mean maximum serum creatinine concentration of 1.5772.04 mg/dl on day 37728. Allogeneic HSCT patients had a high maximum serum creatinine concentration compared to autologous HSCT patients within the 100-day period after HSCT (P ¼ 0.01).
The trends of serum creatinine concentration and creatinine clearance were different between allogeneic and autologous HSCT groups according to time. The graphic representations of the trend in creatinine clearance levels after allogeneic and autologous HSCT are given in Figures  1 and 2 , respectively.
Associated complications with renal dysfunction
The only associated complication of various grades of renal dysfunction in overall HSCT patients was higher frequency of sepsis (26%) (P ¼ 0.001). However, hepatic SOS was found related to development of severe renal dysfunction (P ¼ 0.04). The associated complications of renal dysfunction were then examined based on the type of HSCT (Table 3) . Sepsis was associated with the development of renal dysfunction in autologous HSCT patients (P ¼ 0.015). CsA toxicity was associated with renal dysfunction and hepatic SOS was associated with severe renal dysfunction in allogeneic HSCT patients (P ¼ 0.04 and P ¼ 0.04, respectively).
Univariate analysis comparing patients with renal dysfunction versus normal renal function demonstrated no statistical differences in diagnosis, systolic and diastolic BP levels, conditioning regimens, role of aminoglycosides or amphotericin B. However, mean serum albumin levels of patients with renal dysfunction within the 100 days after CsA toxicity Of 20 patients with allogeneic HSCT who developed various grades of renal dysfunction, eight (40%) had CsA nephrotoxicity. Cyclosporine toxicity was the most associated complication with renal dysfunction in allogeneic HSCT patients (P ¼ 0.04). However, five (25%) of them developed Grade 2 or 3 renal dysfunction. Linear regression of serum creatinine levels compared to simultaneous serum CsA (C0) levels was also demonstrated in graphic representation and revealed no correlation (Figure 3 ).
Sinusoidal obstruction syndrome of the liver
Of the 47 patients, five (11%) met the criteria for SOS and four of them developed SOS after allogeneic HSCT. All patients with SOS of the liver had developed severe renal dysfunction (Grades 2-3) and among them three patients with allogeneic HCT developed Grade 3 renal dysfunction with dialysis requirement. SOS of the liver was associated with severe renal dysfunction (P ¼ 0.04).
Other associated complications with renal dysfunction
In the allogeneic HSCT group, the other contributing factors to renal dysfunction were as follows: HUS (one (5%) patient), amphotericin B neprotoxicity (one (5%) patient). The only patient diagnosed as HUS presented with microangiopathic hemolytic anemia, thrombocytopenia, hypertension, hematuria, proteinuria and renal failure on the 39th day of HSCT and diagnosis of HUS was made clinically. In the autologous HSCT group, the other contributing factors to renal dysfunction were as follows: amphotericin B nephrotoxicity (four (31%) patients), aminoglycoside nephrotoxicity (one (8%) patient) and TLS (one (8%) patient).
Relationship between engraftment and renal dysfunction
The effect of hematopoietic recovery known as engraftment after HSCT on the development of renal dysfunction was also examined. The duration of the neutropenic period was generally 4-5 days shorter in patients receiving autologous HSCT rather than allogeneic HSCT (1176 days (12) versus 1875 days (18) (P ¼ 0.000)). The leukocyte engraftment (the days of leukocyte count 41000/mm 3 ) in patients with normal renal function was achieved earlier compared to patients with renal dysfunction (1273 days (11) versus 1776 days (17) (P ¼ 0.000)). The neutrophil engraftment (the days of neutrophil count 4500/mm 3 ) in patients with normal renal function was achieved earlier compared to patients with renal dysfunction (1273 days (12) versus 1776 days (17) (P ¼ 0.001)). The platelet engraftment (platelet count 420 000/mm 3 ) day did not differ in both groups (P ¼ 0.99).
Mortality
The overall mortality rate for the 47 HSCT patients was 19% (nine of 47) at the end of 100 days. Of these nine patients, five (23%) had received allogeneic HSCT and four (16%) had received autologous HSCT (P ¼ 0.50). The mortalities occurred at an average of 43.7727.6 (51) days after transplantation. In the allogeneic transplant group, mortalities (n ¼ 5) occurred at an average of 58.8723.3 (53) days after transplantation, and in the autologous HSCT group, mortalities (n ¼ 4) occurred at an average of 25721(15) days after transplantation (P ¼ 0.06). The overall mortality rate for the 33 HSCT patients with renal dysfunction was 24% (8/33). Of these eight patients, five had received allogeneic HSCT and three had received autologous HSCT. The mortality rate for patients who developed renal dysfunction (Grades 1-3) was significantly higher than patients with normal renal function (Grade 0) (P ¼ 0.039). Among the eight patients who died within the 100 days after HSCT, six (75%) (four allogeneic, two autologous HSCT) patients were with severe renal dysfunction (Grades 2-3). The mortality rate of patients who exhibited severe renal dysfunction (Grades 2-3) was also higher than patients with Grade 0-1 renal dysfunction; however, this result was not statistically significant (P40.05). Of the eight deceased patients with renal dysfunction, five had sepsis, two had SOS of the liver and one had TLS. Sepsis was associated with the occurrence of mortality in these patients (P ¼ 0.01). There were no differences in any of the different diagnoses and conditioning regimen groups in terms of mortality.
Discussion
Organ toxicities beyond the HSCT are common and potentially life threatening. In this study, we have shown that renal dysfunction is a common and potentially life threatening complication after HSCT. In previous studies, the incidence of renal dysfunction ranged between 56 and 92% in cohorts of patients receiving autologous or allogeneic HSCT, with 20% requiring dialysis. [14] [15] [16] [17] [18] In this study, 70% of the patients had Grade 1-3 renal dysfunctions within the 100 days after HSCT. Of all patients, severe renal dysfunction (Grades 2-3), which can be called as ARF, occurred in 49% of the patients. The incidence of ARF after HSCT in our study is comparable with previous studies mentioned. 
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The present study showed that renal dysfunction was more common in myeloablative allogeneic (91%) than autologous HSCT (52%) (P ¼ 0.004). The differences between the incidences may be due to GVHD and immunosuppressive agents including CsA; neither are involved in autologous HSCT. As CsA is known to be nephrotoxic, this is one potential explanation for the substantial differences in renal dysfunction which appears to result from allogeneic versus autologous cell support. Although some studies report that there may not be a correlation between blood CsA levels and nephrotoxicity, acute CsA-induced renal dysfunction has usually been observed with high blood CsA levels. 15, 19, 20 However, in a recent study, CsA levels were not identified as an independent risk factor for ARF in statistical analysis from four centers. 21 In the present study, CsA nephrotoxicity was the most common cause of renal dysfunction in allogeneic HSCT recipients. Additionally, there were no correlations between short terms of serum CsA concentration increment and creatinine clearance levels within the 20 days after HSCT. However, the renal function in HSCT recipients became worse after the peak period of blood CsA concentration between days 20 and 33 after HSCT. The fact that there is a time lag between the peak CsA concentration and the appearance of the renal dysfunction suggests the presence of variations in total doses of CsA, medical histories and combined drugs used. We should monitor renal function especially within several days after the peak period of the blood CsA concentration and should reduce the CsA dose if necessary.
In our study, time distribution of renal dysfunction differed between allogeneic and autologous HSCT. Recent studies demonstrated that renal dysfunction after HSCT significantly occurs within the first month after HSCT. [3] [4] [5] [6] 14, 15 In our study, renal dysfunction developed later in the setting of allogeneic and autologous HSCT when compared to previous studies. The early time course of the renal dysfunction after autologous HSCT when compared to allogeneic HSCT may have some explanations. During the first 100-day period after HSCT, the peak serum creatinine levels of autologous HSCT patients were observed between 13 and 21 days and the peak serum creatinine levels of allogeneic HSCT patients were observed between 26 and 42 days. Sepsis syndrome-associated renal dysfunction and the concomitant nephrotoxicity risks of antibiotics and antifungal drugs were responsible for the 85% of renal dysfunction in autologous HSCT cases in our study. The renal dysfunction, which was observed mostly between 13 and 21 days of autologous HSCT, was associated with sepsis and concomitant use of neprotoxic drugs including aminoglycoside and amphotericin B. As we examined the effect of engraftment after HSCT on the development of renal dysfunction, we could not find any correlation between time of engraftment and time of renal failure. In recent reports, sepsis and hypotension have been identified as predisposing factors for ARF in patients after BMT. 3, 5, 14 Previous reports suggesting a synergistic nephrotoxicity of amphotericin B, aminoglycosides and renal hypoperfusion during bacteremia are in parallel with our results, which indicate a synergistic effect of different predisposing factors for ARF. 3, [22] [23] [24] Although hypotension is a main risk factor in septic ARF, the present study did not demonstrate a relation between hypotension and renal dysfunction in the setting of autologous HSCT.
In previous reports, renal dysfunction after HSCT contributed to patients mortality. [3] [4] [5] [6] 14, 15 The mortality rate of the patients with renal dysfunction was found to be 24% in the present study. Renal dysfunction is associated with a high risk of mortality in both allogeneic and autologous HSCT. Sepsis was the most common cause of mortality in both allogeneic and autologous HSCT recipients. Thus the association of sepsis and renal dysfunction has ominous implications for patient survival rate. 18 To note from our study, HSCT recipients with low baseline serum albumin levels (o3.5 g/dl) developed more common renal dysfunction but their survival was not changed. As far as we know, this is a new finding in HSCT. Hypoalbuminemia at the time of HSCT may increase the likelihood of ARF, as it modifies Starling's forces in the systemic capillaries, reduces glomerular filtration and alters the pharmacokinetics of potentially nephrotoxic drugs. 25, 26 So we may propose that baseline serum albumin levels before conditioning may be a prognostic factor for renal function during HSCT.
There were several restraints in the present study. The study cohort included a small sample size and hence multivariate analysis could not be performed, which limited our ability to draw conclusions. The effect of TBI on renal function could not be assessed as only two patients had TBI as part of the conditioning. Kidney histological investigation was not performed because of severe hemorrhagic diathesis owing to several reasons, mainly incomplete hematopoietic recovery-related thrombocytopenia and uremia-associated coagulopathy. Urinary electrolytes were also not studied.
Our study indicates that autologous and allogeneic HSCT should be considered as substantially different entities in terms of onset and course of renal dysfunction. Renal dysfunction is more common and more severe during the early period after allogeneic than autologous HSCT and is associated with a high risk of mortality. The use of CsA for GVHD prophylaxis and a high incidence of SOS of the liver in allogeneic HSCT may have role in this outcome. Close monitoring of renal function especially within several days after the peak period of the blood CsA concentration and reducing the CsA dose if necessary may prevent renal dysfunction after allogeneic HSCT. After autologous HSCT, synergistic effect of different predisposing factors including especially sepsis and nephrotoxicity of drugs may contribute to development of early renal dysfunction. Sepsis was the most common cause of death in both types of transplantation. The association of sepsis and renal dysfunction has an unfavorable effect on mortality rate, and baseline serum albumin level before HCT may be a prognostic indicator of patients' renal functions.
